ZHU GAOZHONG,LOWE KRIS,SHAHROKH ZAHRA,PAN JING,WRIGHT TERESA LEAH,CALIAS PERICLES,FAHRNER RICK,CHRISTIAN JAMES
申请号：
NZ70280811
公开号：
NZ702808A
申请日:
2011.06.25
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is the use of an iduronate-2-sulfatase (I2S) protein in the manufacture of a formulation for the treatment of Hunters Syndrome, wherein treatment includes intrathecal administration of the formulation to a subject in need of treatment, wherein the formulation comprises an iduronate-2-sulfatase (I2S) protein at a concentration at or greater than about 5 mg/ml, and wherein the formulation comprises no greater than 50 mM of phosphate.
